Marc. you, Thank
call conference only ago. last weeks was X Our
update During and I about R&D Elite's Elite's safety, facility make I'll then the go to two-and-a-half In a I'll update, next then two, on we'll that Q&A. financials, our few commercial today's comments pipeline, products, goals call, you outlined for years. manufacturing and
our this stated, for quarter were revenues $X.X Marc As million.
million the quarter not last that? think million recall, we you declined, and were was inventory, wasn't in Lannett That of in $X If quarter the March do ending last we they because did where had sales same. the profit were the I replace range, from in $X Why got and sales was range, the split it about because in Because the $X the all. that XXXX. before, what quarter million sold
the as getting and determines pharmaceutical Marc the to that in Company effect fast talked you have downside the they they money. a sometimes inventory practice build is standard for industry it industry, a and way this sometimes pharmaceutical it and and Depleting too, from and is better. well. sales all is of line reach practice and bottom are and the the Amphetamine does are. the The about, see So ER deplete how much they equilibrium in when the have from Depleting its raise they team a profit standard but it following, solid sales, money the it IR
earned for million revenues to know, As Last to XX ago, that year yet year million was years million went in be the ever million the dollars. profit million to and when best our up our the ever split. you revenues, best that became from believe best year last ever. is from revenues Elite. in year year $XX X in revenues Two XX shaping up we years $XX current I $X.X
It was shares and better than worst stock when business, sell when understand proportional profitable, to would to do of I performance; we are not higher were rationale revenues self-sufficient, and things prices, self-sustaining. is stock now survive movement. this that be lead but the our to the to broke higher we the You understand Elite's the gets. had to The it do, seems for we would stock about lot I a higher stock profits inversely and think
I you all, the of a you sector price as companies at majority look stock have genetic the been if you'll the DAVA, past majority and As I the before, XX% over that this Lannett, stocks; the declined over depressed find whole, X Perrigo, of -- looked XX% the X Teva, in morning: Aimil value of stocks the years. and at past and X compared between updated not the years. X
have credit or Dr. While we're only the Teva. negative, recovered Elite, of P/E the have past is they model, everybody earnings a just XX% over Reddy That's but part to because Reddy X following X by their interesting companies pattern money. business and increased their most is Lannett, ahead. P/E has so their or the Amneal and more in The be and over per from as negative past positive a else, years. 's declined their one, X share they over $X.XX ratio. losing Amneal XX, Reddy's XX. and Dr. Reddy the the Perrigo, Dr. and there industry, X increased Dr. P/E year-and-a-half $X.XX past like same changed P/E is the are ratio; years, $X.X got ratio ratios. accurate, they're to to
three If Reddy that and X. is Dr. we other not like treated the like Amneal, ratio are are P/E losing money. Our
This course, price other based a up, $X.XX today, Company's well, go valuation, to Just will due turn, the employees fair we $X.XX is with in as time Amneal, used the should need stay take would be, and there metrics stock our our low we our in are those debt. or an of safety. are example the metrics like have assess focused to very business, their and metric for just substituting and stock stay well employee we care Dr. very the not and value, will The on and for P/E tide be that Reddy starting only meantime, ours. Company under ratio
of pandemic every safety, are affecting sales pandemic. affecting Regarding not it's supplier, us, our COVID-XX business. only is marketing a our and is Elite, a it service in affecting in providers, once-in-a-lifetime we that partners, business, and is all operating
conference we conditioning to air And our social All employees, We increased and and we elite get yet, possible, the guidelines ensure local office. for bacteria ventilation The system, heating business our and many distance have UV they the are are Team following protected to do employees and non-essential Most are still paid the Elite, employees COVID our as to much as materials. and are lamps federal not via vaccinated, affected it them, protecting they must we materially because sources our Microsoft of killed option that would airflow meetings same CDC and manufacturing by has or and for addition given viruses installed asking circulation, someone business. in an enter been reach we from we've calls a be recommendations. if multiple in holding are employees off. in have everyone invested hyperfiltration, that suite At before with home. We else's been to work have they of
likely going endemic. An coming infected of case very problem get to with endemic go it accordingly around on single still be is to and even therefore, our -- every API We the talk. we Elite for source, hard I Latin scares flourish could because to continue. update is America. to from even generations, s able have be up rid COVID-XX, I we country business and manage this to U.S. continues India with a from and to me a certain parts, of need my you a that and because why I move pandemic components hope time could epidemic going or buys that into that ball the is This China, well, an make to that have is severe that's the of been we it an the eye safety API most be we in and to some U.S. manage and virus, that in when on from it's a disease
with is effort to marketing and with they new our to only provide commercial objective can it. commercial our product R&D sales they [Indiscernable] On our joint our front, part of product and and our continuing improving grow pipeline. can the The And current line Protecting the do compete market we of purchase by We is R&D that so is need profitability. and reasonable penetrate that in /or investing to a compete. And product. products. protection with them key a a course, partner. part That's
Now, expanding recap. ago, shared so line me -- with of the weeks R&D. is Elite's you a X goal X years let product I function
capital, we R&D product is into right or purchases. have our to the invested the I to to R&D literally because years in working lately. goal lucrative vaccine the and money me continue Our over upgrade facilities. to portfolio, X.X be cannot go that. stay adequate telling happening cash be business it's and that's rest continue our from what's new will fits advice facility, next stakeholders can In the We maintain flow-positive, that select profitability, made the get of our our product do and at manufacturing
example, that run it injectable water of substances configured or fit trial, a or non-controlled care the would lot product requires that engineering, Once year. orally end unless laminar For offering takes promising, we make we're creams, and the and and of and release, air, somebody before tablet because the not the that control, you a begin and fact purified a within not either things on extended-release, facility. We These going injectables, We or the pass time different product understand and would clinical before opportunity capsule controlled instant administrated, bacterial we're looking we plan for. this of you'll the that and have years. that our of identify technology ointments. keep I'm that. reverse Opportunities portfolio. are take to we are telling are That of is totally or the to us high do delayed-release, standard. I'm money pivotal include
and not you know life been on. formulations clinical which working or a a these public scientists, SunGen, trial behind for materialize process, scenes second, the the We you about file. may the trial, time not have do rate development filing, that things encounter success of first, successful because work great clinical fail Many XX% multiple and on us confirm We long the time does or the finally before the products of get was the they lot hear. into products. third on throughout a with of do or you clinical about had worked trials
is ANDAs to and/or December goal before pass XXXX. Our file X
XXXX. must ANDAs You can in math on determine how the or ANDAs X viable do have on and to many get be we worked working
first, the reworked. be time waste. be let not do second that can Now, The me clear. They work are formulations not a
more to back more you to year You delays, not and conduct learn the process try on costs and as to by a hopefully, from then we This file the and while can permitting, clinical in of time, of will approvals thriving But errors is will NASDAQ. four Financially well, you the critical that do trials next we what for. part again. be money. intend and four come and do, this plan and we first and learn ANDAs, labels getting filed, getting four
Lannett On the partners and well continue IR this doing are we profit, highest profitable front, is market cannot to profitability, at our are contributors and be continuing to do sales the commercial penetration. alone. marketing key products we to and commercial and Amphetamine and revenues ER
continue. date, I and have Epic. Each limited partner, X These not had to we previous one to we believe This expect they are give partner, Trimipramine quarter's competitor interesting our in one have the with profit deserve. because competition. trend highest split they them attention products market. Isradipine has was only our the was to Glenmark, that the and are able
head We why of when and in or XX the marketing me Isradipine you're the you the expect about market more to cost, penetration with products, is reverted market were here. make it. It hope there's market, the as selling Naltrexone way approved, KVK, the effective is one Bariatrics. the to Federal were FDA, when the and X, got of are only let these comment That's of we know and compared products in And which XX, and KVK the of Tagi their about which how a larger when to And the from a it's be indicted, with has solve share about problems their in trouble supplier in FDA, a Epic Tagi have approved have ANDA sales But that price was we the the will that XX% millions. FDA products. and XX. that we They Actavis margin the and adjustment. cheaper, for using little capture small that running them competing Epic, well Bariatrics they players. the to Trimipramine. a making by were selling instead Hydroxyzine. they not at Mexico, we KVK hoping owner these handle the second their is to because bought market, with sell was Glenmark doing were not of with But apparently Government. that quality lot of above and the
is that and on Pharmaceutical. Burel list, Does our the that. continue So the there, capsules Loxapine Elite. that Prasco investigation, products. with to growth they the well [Indiscernable] them Prasco FDA new materialize be product the Elite could we is label under and hope and FDA Loxapine product business are approvals, and executing and for launching obtaining does Prasco June under plans, monetary Federal Government partner launched in Loxitane, to with we've indicted
is year? Was referring is buying the both. that with please calendar next to drug, plan as the enough biotechnology, filed on manufacturing, stated X would to pipeline. partners and well. In our XXXX; We as he categories. it's our or received a AMVAs, opportunities, to X We the go Can the look and performing buying start Elite develop of I or here, CC, are successful group the Actually, last the picky market forward X whether several ahead wish in types developing, color and questions more we submitted year. Getting always, years. Dianne, in-house? assets/drugs first that calendar fiscal all another that provide be use to you put them ANDAs of go or each evaluates ANDAs own developing marketing was that generally Is be most it the to of I'll Elite of there is own sales the additional year. contract in developing lot into ANDAs, considering find kind not? I Our or and will of could. type size, attractive. Nasrat
I First, we ago, this a I let's for competitive say for explained and few dozen year. but projects, as second, reasons, can't, a four ends minutes run up
or are may know impact. you Hakim end but And promise the be is also information So and having a not companies into portfolio. can materials source release, contain and Elite or our question which I since be really medications? COVID in extended-release don't up all concerns this, Company being will might concern may the four that India, a I are capsules, they call, fit will their to Asia. last these appropriate. ones, disclose manufacture raw or that to going still API problems COVID Our it's many controlled other the we API will substance, able it from over tablets there delayed-release, when and is The is conference different sourced API or Mr. mentioned to with spread Europe instant
in interruption supply and and not CT not encountered, put was COVID, have the really did material. We We was chain hold, experienced That COVID-XX. on and paused, we've results a the trial of of clinical that interruption completed because a continued whatever part result India have of were then is one provided. as of part
there they concern in concern because my impact are material flavors, it issue bigger questions I'm than a that. As of I'll not to read Adderall. today to going the had then several address lingers problem on be it And to future? concern answer from before We I for is. about already them and now becomes pandemic stated is be ready as X that I'll different this we is because My Elite. have before, a is today, no absolutely on, trying
on. this really doing to -- showing Can great may true, start penetration great is level? ER That the sales. go product correct. about you us the has As shed next Not some market let's the for the why significant market is pushed drug as that Adderall XX product but has moving the which Lannett generic as been in now should hardly IR is to the months penetration, be showed and any market light what have is been this to
it holding is Adderall Lannett to for what us as in or Is market? expectation decent a are If are the marketing. the seeing tough you ER? are revenues earnings multiple insight have I the do of sales as potential what what products? May generic Our guidance we of or on of expecting. they the Adderall to contribution sales quota not and what from I were to back DEA XXXX? relative blame be Lannett, penetrating limitation don't want I is Well, the job not, Okay. from its because Lannett and or standpoint doing believe us flat
frame top competitors the And let everyone right and there So Walgreen, XX and me McKesson. in are CVS, companies, trying to ER. Each Health, the has X the this Amphetamine and other in get competitors. and Cardinal and is and into form. IR Walmart, outbid
last other by were The was a not fight. four, the they a President delayed we had of But first one FDA our a the little problem recall, four. you're we to We don't the eight. penetration. impact, there got, resources, much. number to blame we shut rationing services a number are is the were application of by bigger did want and we actually much and them be entry. encountered of really got competitors bit have to and give at somebody if time competitors, portion time. a Lannett, it's When government, year. the control fight, that delayed you that three There market give minimal eight We down where the That supposed not it's when product you was you Trump
on. So whenever waited explain the at penetration, let me we Actavis, bids that. market my In when have came days we
a drugs call day single or example, bid on every you products from say, year. cheaper. have if products buy them does CVS CVS. for once people they not can to Let's certain They see
come the done have got me you of year, lower with lately that the put they to forbid with in and it For what late a they or you negotiate say, contract you and others. rest try till for price
the every product year X Lannett how a only in, bid, is single need you and tells more or when pricing. you So that go than from has see time or old, it how little only to higher, or you learn shops a X had that adjust a you getting and lower to
will way get Now, of I maybe revenues the they penetrated IR well expectations we market, XXXX, expect, matter expect them was my I into ER, into IR the as much the in it's and from a very game and to frankly, do later. said first much, earlier, have the because grow. didn't time, until approval profit the with the same split I and just and ER beyond
consider believe time. they absolutely cut really and This that bonus that salary line taking funny. HN impact marketing, get salary then the we his product their basket they next been is and about their There's Walgreen's bring Elite's question worth to Let re-evaluated it share Costco the impacted? not sell profitable, Lannett we that question. of products door, not Another in purchase they low not have and stocks. on give or products on the as don't can down cutting are Every in that The category. no Lannett really in drug several do to to wherever, they in with Lannett, or any then profitable an use them but other them and are question products has Company are profit, Will all-cash, will that is sell Elite whatsoever, products explain so foot market? there. the about in payment into me a a or and open their the
to my A free. half the Marc issued and of changed see starter to piece They to just one for me and the is the hope would store salary love work to XXX% is half work pay cash at to stocks, I I Elite. year. all the board is Board at back, a my now my get funny. salary, XX% goes XX% somewhere. which while used of compensation in pay the meant to -- part and first of to valid, of that The and I I of half, year, had equivalent XXX% the second to end in half now in so used government, next paper I the that
I've Now, never for is the million we a things money, order the that, now day, that lot because Marc's of with profitable of not to when reason at in number. R&D, the end why you pushed saw doing need of the a dollars. heck we're we're even money That's numbers, and for increase a Mikah we other that's make and partnering
to making more me I are cash actually much taking me, profitable, do into it. heart we have to please bank. nothing it the for So to All and don't that, When be than right. would tap the
the in Another answered Mikah. quarters. have question X every purchase SunGen Adderall the and I quarter ownership question. for single the quarter, everybody every of about that asks past single Again,
you wish this and because back is being now, asked If transcripts. I go answer, to am going all right to read to just issue address again be the asked. not question hear the
that, the thank that board's and Amphetamine that's with -- development Mikah Marc, this, another Mikah's than could better addressed has purchased comment agreement this, Carter IR on so for We're take you addressed share and you. ER, please? this. SunGen's that. with much in Company [Indiscernable] done us doing it. included addressed have the We've We Please is purchased
